drugset / Trial / NCT00942136
GSK1349572 Proton Pump Inhibitor Drug Interaction and Supratherapeutic Dose Study
RandomizedParallel-groupOpen-labelTreatment
Summary
GSK1349572 is an integrase inhibitor that is currently being evaluated for the treatment of HIV infection. The primary objective of this study is to determine whether the addition of a proton pump inhibitor, omeprazole, to GSK1349572 impacts the blood levels of GSK1349572. It will also evaluate if a high fat meal impacts the blood levels of GSK1349572. In addition, the safety, tolerability, and pharmacokinetics of single supratherapeutic (high) dose of GSK1349572 will be evaluated.
Timeline
- Start
- 2009-07
- Primary completion
- 2009-09
- Completion
- 2009-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dolutegravir | Other / unclassified | 50 mg | — |
| Subject | Dolutegravir | Other / unclassified | 250 mg | — |
| Subject | Omeprazole | Other / unclassified | 40 mg | — |
Indications
No indication recorded.